[Oral @entity898 in the treatment of XXXX secondary to @entity785 : a randomized, double-blind, placebo-controlled clinical trial].

@entity1 @entity1066 @entity898 @entity2407 @entity785
OBJECTIVE: To evaluate the safety and efficacy of @entity898 (NAC) orally on digital microcirculation blood flow in @entity1 with @entity2407 ( @entity2407 ) secondary to @entity785 ( @entity785 ). METHODS: This was a randomized, double-blind, placebo-controlled trial in which 42 @entity1 with @entity785 received oral NAC at a dose of 600mg tid (21 @entity1 , mean age 45.6  9.5 years) or placebo (21 @entity1 , mean age 45.0  12.7 years) for four weeks. The primary endpoint was the change in cutaneous microcirculation blood flow before and after cold stimulation measured by laser Doppler imaging (LDI) at weeks 0 and 4. The frequency and severity of @entity2407 and the number of digital @entity1066 were also measured at weeks 0 and 4. The adverse events were recorded in the fourth week. RESULTS: There was no significant change in digital blood flow assessed by LDI before or after cold stimulus after four weeks of NAC or placebo. Both groups showed significant improvement in the frequency and severity of @entity2407 attacks, with no difference between the two groups. At the end of the study, the placebo group had three digital @entity1066 , while the NAC group showed no @entity1066 . NAC was well tolerated and no @entity1 discontinued the treatment. CONCLUSIONS: NAC orally at a dose of 1800mg/day showed no vasodilator effect on hands' microcirculation after four weeks of treatment in @entity1 with @entity2407 secondary to @entity785 .
